Enovis (NYSE:ENOV) Stock Rating Upgraded by Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other equities research analysts also recently commented on the company. Citizens Jmp decreased their price objective on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Wednesday, September 2nd. BTIG Research cut their target price on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, September 1st. Evercore set a $32.00 price target on shares of Enovis in a research report on Monday, July 6th. Canaccord Genuity Group decreased their price target on shares of Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, August 17th. Finally, Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $40.38.

Enovis Price Performance

Shares of NYSE ENOV opened at $19.54 on Friday. The firm has a market capitalization of $1.13 billion, a P/E ratio of -1.01 and a beta of 1.31. The firm’s 50-day moving average price is $25.25 and its 200-day moving average price is $24.11. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis has a 1-year low of $18.08 and a 1-year high of $34.28.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same period last year, the business posted $0.79 EPS. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts anticipate that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert purchased 2,660 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was acquired at an average cost of $18.80 per share, with a total value of $50,008.00. Following the transaction, the insider owned 63,898 shares of the company’s stock, valued at $1,201,282.40. This represents a 4.34% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Damien Mcdonald acquired 13,035 shares of the company’s stock in a transaction on Friday, September 4th. The shares were bought at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. This represents a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 23,293 shares of company stock valued at $449,599 in the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Arax Advisory Partners bought a new stake in Enovis in the 4th quarter worth about $29,000. IFP Advisors Inc lifted its position in shares of Enovis by 5,590.5% during the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after buying an additional 1,174 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the last quarter. Allworth Financial LP purchased a new position in shares of Enovis in the 2nd quarter worth approximately $36,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Enovis in the second quarter valued at approximately $39,000. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.